Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma Article Swipe
Clémentine Sarkozy
,
Mary Callanan
,
Catherine Thiéblemont
,
Lucie Obéric
,
Barbara Burroni
,
Krimo Bouabdallah
,
Gandhi Damaj
,
Benoît Tessoulin
,
Vincent Ribrag
,
Roch Huout
,
Franck Morschhauser
,
Samuel Griolet
,
Clémentine Joubert
,
Victoria Cacheux
,
Vincent Delwail
,
Violaine Safar
,
Rémy Gressin
,
Morgane Cheminant
,
Marie‐Hélène Delfau‐Larue
,
Olivier Hermine
,
Elizabeth Macintyre
,
Steven Le Gouill
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1182/blood.2024023944
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1182/blood.2024023944
Obinutuzumab (O) and rituximab (R) are 2 CD antibodies that have never been compared in a prospective randomized trial of mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LyMa-101 trial, in which newly diagnosed patients with MCL were treated with chemotherapy plus O before transplantation, followed by O maintenance (O group). We then compared these patients with those treated with the same treatment design with R instead of O (R group). A propensity score matching (PSM) was used to compare the 2 populations (O vs R groups) in terms of measurable residual disease (MRD) at the end of induction (EOI), progression-free survival (PFS), and overall survival (OS). In LyMa-101, the estimated 5-year PFS and OS after inclusion (n = 85) were 83.4% (95% confidence interval [CI], 73.5-89.8) and 86.9% (95% CI, 77.6-92.5), respectively. At EOI, patients treated in the O group had more frequent bone marrow MRD negativity than those treated in the R group (83.1% vs 63.4%; χ2, P = .007). PSM resulted in 2 sets of 82 patients with comparable characteristics at inclusion. From treatment initiation, the O group had a longer estimated 5-year PFS (P = .029; 82.8% vs 66.6%; hazard ratio [HR], 1.99; 95% confidence interval (CI), 1.05-3.76) and OS (P = .039; 86.4% vs 71.4%; HR, 2.08; 95% CI, 1.01-4.16) compared with the R group. Causes of death were comparable in the 2 groups, the most common cause being lymphoma. O before transplantation and in maintenance provides better disease control and enhances PFS and OS compared with R in transplant-eligible patients with MCL. These trials were registered at www.clinicaltrials.gov as #NCT00921414 and NCT02896582.
Related Topics
Concepts
Mantle cell lymphoma
Obinutuzumab
Rituximab
Medicine
Oncology
Internal medicine
Ibrutinib
Lymphoma
Chronic lymphocytic leukemia
Leukemia
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1182/blood.2024023944
- OA Status
- green
- Cited By
- 9
- References
- 18
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4395677193
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4395677193Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1182/blood.2024023944Digital Object Identifier
- Title
-
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-04-26Full publication date if available
- Authors
-
Clémentine Sarkozy, Mary Callanan, Catherine Thiéblemont, Lucie Obéric, Barbara Burroni, Krimo Bouabdallah, Gandhi Damaj, Benoît Tessoulin, Vincent Ribrag, Roch Huout, Franck Morschhauser, Samuel Griolet, Clémentine Joubert, Victoria Cacheux, Vincent Delwail, Violaine Safar, Rémy Gressin, Morgane Cheminant, Marie‐Hélène Delfau‐Larue, Olivier Hermine, Elizabeth Macintyre, Steven Le GouillList of authors in order
- Landing page
-
https://doi.org/10.1182/blood.2024023944Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://hal.univ-lille.fr/hal-04603772/documentDirect OA link when available
- Concepts
-
Mantle cell lymphoma, Obinutuzumab, Rituximab, Medicine, Oncology, Internal medicine, Ibrutinib, Lymphoma, Chronic lymphocytic leukemia, LeukemiaTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
9Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 6, 2024: 3Per-year citation counts (last 5 years)
- References (count)
-
18Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4395677193 |
|---|---|
| doi | https://doi.org/10.1182/blood.2024023944 |
| ids.doi | https://doi.org/10.1182/blood.2024023944 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38669626 |
| ids.openalex | https://openalex.org/W4395677193 |
| fwci | 8.24228916 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D020522 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[2].qualifier_ui | Q000401 |
| mesh[2].descriptor_ui | D020522 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | mortality |
| mesh[2].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[3].qualifier_ui | Q000628 |
| mesh[3].descriptor_ui | D020522 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | therapy |
| mesh[3].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[4].qualifier_ui | Q000473 |
| mesh[4].descriptor_ui | D020522 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | pathology |
| mesh[4].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[5].qualifier_ui | Q000008 |
| mesh[5].descriptor_ui | D000069283 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | administration & dosage |
| mesh[5].descriptor_name | Rituximab |
| mesh[6].qualifier_ui | Q000627 |
| mesh[6].descriptor_ui | D000069283 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | therapeutic use |
| mesh[6].descriptor_name | Rituximab |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008297 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Male |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D005260 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Female |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D008875 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Middle Aged |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D061067 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[11].qualifier_ui | Q000008 |
| mesh[11].descriptor_ui | D061067 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | administration & dosage |
| mesh[11].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000368 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Aged |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D000074322 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[14].qualifier_ui | Q000008 |
| mesh[14].descriptor_ui | D000074322 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | administration & dosage |
| mesh[14].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[15].qualifier_ui | Q000009 |
| mesh[15].descriptor_ui | D000074322 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | adverse effects |
| mesh[15].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D000328 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Adult |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D018380 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Hematopoietic Stem Cell Transplantation |
| mesh[18].qualifier_ui | Q000627 |
| mesh[18].descriptor_ui | D000971 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | therapeutic use |
| mesh[18].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000077982 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Progression-Free Survival |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D018365 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Neoplasm, Residual |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D011446 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Prospective Studies |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D006801 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Humans |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D020522 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[24].qualifier_ui | Q000401 |
| mesh[24].descriptor_ui | D020522 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | mortality |
| mesh[24].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[25].qualifier_ui | Q000628 |
| mesh[25].descriptor_ui | D020522 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | therapy |
| mesh[25].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[26].qualifier_ui | Q000473 |
| mesh[26].descriptor_ui | D020522 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | pathology |
| mesh[26].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[27].qualifier_ui | Q000008 |
| mesh[27].descriptor_ui | D000069283 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | administration & dosage |
| mesh[27].descriptor_name | Rituximab |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000069283 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Rituximab |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D008297 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Male |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D005260 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Female |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D008875 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Middle Aged |
| mesh[32].qualifier_ui | Q000627 |
| mesh[32].descriptor_ui | D061067 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | therapeutic use |
| mesh[32].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[33].qualifier_ui | Q000008 |
| mesh[33].descriptor_ui | D061067 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | administration & dosage |
| mesh[33].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D000368 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Aged |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D000074322 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[36].qualifier_ui | Q000008 |
| mesh[36].descriptor_ui | D000074322 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | administration & dosage |
| mesh[36].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[37].qualifier_ui | Q000009 |
| mesh[37].descriptor_ui | D000074322 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | adverse effects |
| mesh[37].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D000328 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Adult |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D018380 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Hematopoietic Stem Cell Transplantation |
| mesh[40].qualifier_ui | Q000627 |
| mesh[40].descriptor_ui | D000971 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | therapeutic use |
| mesh[40].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D000077982 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Progression-Free Survival |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D018365 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Neoplasm, Residual |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D011446 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Prospective Studies |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D006801 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Humans |
| mesh[45].qualifier_ui | Q000188 |
| mesh[45].descriptor_ui | D020522 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | drug therapy |
| mesh[45].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[46].qualifier_ui | Q000401 |
| mesh[46].descriptor_ui | D020522 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | mortality |
| mesh[46].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[47].qualifier_ui | Q000628 |
| mesh[47].descriptor_ui | D020522 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | therapy |
| mesh[47].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[48].qualifier_ui | Q000473 |
| mesh[48].descriptor_ui | D020522 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | pathology |
| mesh[48].descriptor_name | Lymphoma, Mantle-Cell |
| mesh[49].qualifier_ui | Q000008 |
| mesh[49].descriptor_ui | D000069283 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | administration & dosage |
| mesh[49].descriptor_name | Rituximab |
| type | article |
| title | Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma |
| biblio.issue | 3 |
| biblio.volume | 144 |
| biblio.last_page | 271 |
| biblio.first_page | 262 |
| topics[0].id | https://openalex.org/T10185 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Lymphoma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T11157 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9998000264167786 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Chronic Lymphocytic Leukemia Research |
| topics[2].id | https://openalex.org/T10685 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9994999766349792 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Viral-associated cancers and disorders |
| is_xpac | False |
| apc_list.value | 5000 |
| apc_list.currency | USD |
| apc_list.value_usd | 5000 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777525834 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8260825872421265 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q268713 |
| concepts[0].display_name | Mantle cell lymphoma |
| concepts[1].id | https://openalex.org/C2777607594 |
| concepts[1].level | 4 |
| concepts[1].score | 0.7665009498596191 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q389496 |
| concepts[1].display_name | Obinutuzumab |
| concepts[2].id | https://openalex.org/C2780653079 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7481039762496948 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[2].display_name | Rituximab |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.6866518259048462 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5135722160339355 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5069177746772766 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2779878957 |
| concepts[6].level | 4 |
| concepts[6].score | 0.4857342839241028 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q5984881 |
| concepts[6].display_name | Ibrutinib |
| concepts[7].id | https://openalex.org/C2779338263 |
| concepts[7].level | 2 |
| concepts[7].score | 0.3738767206668854 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[7].display_name | Lymphoma |
| concepts[8].id | https://openalex.org/C2777938653 |
| concepts[8].level | 3 |
| concepts[8].score | 0.16217094659805298 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1088156 |
| concepts[8].display_name | Chronic lymphocytic leukemia |
| concepts[9].id | https://openalex.org/C2778461978 |
| concepts[9].level | 2 |
| concepts[9].score | 0.15688112378120422 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q29496 |
| concepts[9].display_name | Leukemia |
| keywords[0].id | https://openalex.org/keywords/mantle-cell-lymphoma |
| keywords[0].score | 0.8260825872421265 |
| keywords[0].display_name | Mantle cell lymphoma |
| keywords[1].id | https://openalex.org/keywords/obinutuzumab |
| keywords[1].score | 0.7665009498596191 |
| keywords[1].display_name | Obinutuzumab |
| keywords[2].id | https://openalex.org/keywords/rituximab |
| keywords[2].score | 0.7481039762496948 |
| keywords[2].display_name | Rituximab |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.6866518259048462 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.5135722160339355 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.5069177746772766 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/ibrutinib |
| keywords[6].score | 0.4857342839241028 |
| keywords[6].display_name | Ibrutinib |
| keywords[7].id | https://openalex.org/keywords/lymphoma |
| keywords[7].score | 0.3738767206668854 |
| keywords[7].display_name | Lymphoma |
| keywords[8].id | https://openalex.org/keywords/chronic-lymphocytic-leukemia |
| keywords[8].score | 0.16217094659805298 |
| keywords[8].display_name | Chronic lymphocytic leukemia |
| keywords[9].id | https://openalex.org/keywords/leukemia |
| keywords[9].score | 0.15688112378120422 |
| keywords[9].display_name | Leukemia |
| language | en |
| locations[0].id | doi:10.1182/blood.2024023944 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S200071133 |
| locations[0].source.issn | 0006-4971, 1528-0020 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0006-4971 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Blood |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Blood |
| locations[0].landing_page_url | https://doi.org/10.1182/blood.2024023944 |
| locations[1].id | pmid:38669626 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Blood |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38669626 |
| locations[2].id | pmh:oai:HAL:hal-04603772v1 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306402512 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| locations[2].source.host_organization | https://openalex.org/I1294671590 |
| locations[2].source.host_organization_name | Centre National de la Recherche Scientifique |
| locations[2].source.host_organization_lineage | https://openalex.org/I1294671590 |
| locations[2].license | cc-by-nc |
| locations[2].pdf_url | https://hal.univ-lille.fr/hal-04603772/document |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Journal articles |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Blood, 2024, Online ahead of print. ⟨10.1182/blood.2024023944⟩ |
| locations[2].landing_page_url | https://hal.univ-lille.fr/hal-04603772 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5044269394 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1942-9304 |
| authorships[0].author.display_name | Clémentine Sarkozy |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I80043 |
| authorships[0].affiliations[0].raw_affiliation_string | Institut Curie, Hematology department, Saint Cloud, France |
| authorships[0].institutions[0].id | https://openalex.org/I80043 |
| authorships[0].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[0].institutions[0].type | nonprofit |
| authorships[0].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Institut Curie |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Clémentine Sarkozy |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Institut Curie, Hematology department, Saint Cloud, France |
| authorships[1].author.id | https://openalex.org/A5103105005 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9088-0720 |
| authorships[1].author.display_name | Mary Callanan |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I177064439 |
| authorships[1].affiliations[0].raw_affiliation_string | University of Burgundy-INSERM 1231-CHU Dijon, DIJON, France |
| authorships[1].institutions[0].id | https://openalex.org/I154526488 |
| authorships[1].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[1].institutions[0].type | government |
| authorships[1].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Inserm |
| authorships[1].institutions[1].id | https://openalex.org/I177064439 |
| authorships[1].institutions[1].ror | https://ror.org/03k1bsr36 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I177064439 |
| authorships[1].institutions[1].country_code | FR |
| authorships[1].institutions[1].display_name | Université de Bourgogne |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mary Bridgid Callanan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | University of Burgundy-INSERM 1231-CHU Dijon, DIJON, France |
| authorships[2].author.id | https://openalex.org/A5033073385 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9941-2448 |
| authorships[2].author.display_name | Catherine Thiéblemont |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210097159, https://openalex.org/I4210144610 |
| authorships[2].affiliations[0].raw_affiliation_string | AP-HP, Hôpital Saint-Louis, Hemato-oncologie, DMU DHI,F-75010 Paris, France, Paris, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[2].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[2].institutions[1].id | https://openalex.org/I4210144610 |
| authorships[2].institutions[1].ror | https://ror.org/049am9t04 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210144610 |
| authorships[2].institutions[1].country_code | FR |
| authorships[2].institutions[1].display_name | Hôpital Saint-Louis |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Catherine Thieblemont |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | AP-HP, Hôpital Saint-Louis, Hemato-oncologie, DMU DHI,F-75010 Paris, France, Paris, France |
| authorships[3].author.id | https://openalex.org/A5009487344 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0039-1983 |
| authorships[3].author.display_name | Lucie Obéric |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210098740 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France |
| authorships[3].institutions[0].id | https://openalex.org/I4210098740 |
| authorships[3].institutions[0].ror | https://ror.org/014hxhm89 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210098740 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Institut universitaire du cancer de Toulouse Oncopole |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lucie Obéric |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse, France |
| authorships[4].author.id | https://openalex.org/A5079523601 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Barbara Burroni |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210092774 |
| authorships[4].affiliations[0].raw_affiliation_string | Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210092774 |
| authorships[4].institutions[0].ror | https://ror.org/00ph8tk69 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210092774, https://openalex.org/I4210097159, https://openalex.org/I4210124464 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Hôpital Cochin |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Barbara Burroni |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France |
| authorships[5].author.id | https://openalex.org/A5068452218 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4425-7823 |
| authorships[5].author.display_name | Krimo Bouabdallah |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I3018323443 |
| authorships[5].affiliations[0].raw_affiliation_string | CHU de Bordeaux, France |
| authorships[5].institutions[0].id | https://openalex.org/I3018323443 |
| authorships[5].institutions[0].ror | https://ror.org/01hq89f96 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I3018323443 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Centre Hospitalier Universitaire de Bordeaux |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Krimo Bouabdallah |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | CHU de Bordeaux, France |
| authorships[6].author.id | https://openalex.org/A5062422990 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-4689-3882 |
| authorships[6].author.display_name | Gandhi Damaj |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I98702875 |
| authorships[6].affiliations[0].raw_affiliation_string | Normandy University, Hematology Institute, Caen, France |
| authorships[6].institutions[0].id | https://openalex.org/I98702875 |
| authorships[6].institutions[0].ror | https://ror.org/051kpcy16 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210105918, https://openalex.org/I98702875 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Université de Caen Normandie |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ghandi Damaj |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Normandy University, Hematology Institute, Caen, France |
| authorships[7].author.id | https://openalex.org/A5078197703 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7600-3329 |
| authorships[7].author.display_name | Benoît Tessoulin |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I97188460 |
| authorships[7].affiliations[0].raw_affiliation_string | Nantes University Hospital, Nantes, France |
| authorships[7].institutions[0].id | https://openalex.org/I97188460 |
| authorships[7].institutions[0].ror | https://ror.org/03gnr7b55 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I97188460 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Nantes Université |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Benoit Tessoulin |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Nantes University Hospital, Nantes, France |
| authorships[8].author.id | https://openalex.org/A5032462496 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-5221-353X |
| authorships[8].author.display_name | Vincent Ribrag |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[8].affiliations[0].raw_affiliation_string | Institut Gustave Roussy, Villejuif, France |
| authorships[8].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[8].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Institut Gustave Roussy |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Vincent Ribrag |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Institut Gustave Roussy, Villejuif, France |
| authorships[9].author.id | https://openalex.org/A5095908149 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Roch Huout |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210155724, https://openalex.org/I56067802 |
| authorships[9].affiliations[0].raw_affiliation_string | CHU Rennes, University of Rennes, Rennes, France |
| authorships[9].institutions[0].id | https://openalex.org/I4210155724 |
| authorships[9].institutions[0].ror | https://ror.org/05qec5a53 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210155724 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Centre Hospitalier Universitaire de Rennes |
| authorships[9].institutions[1].id | https://openalex.org/I56067802 |
| authorships[9].institutions[1].ror | https://ror.org/015m7wh34 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I56067802 |
| authorships[9].institutions[1].country_code | FR |
| authorships[9].institutions[1].display_name | Université de Rennes |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Roch Huout |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | CHU Rennes, University of Rennes, Rennes, France |
| authorships[10].author.id | https://openalex.org/A5051605599 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-3714-9824 |
| authorships[10].author.display_name | Franck Morschhauser |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2279609970 |
| authorships[10].affiliations[0].raw_affiliation_string | University of Lille, Lille, France |
| authorships[10].institutions[0].id | https://openalex.org/I2279609970 |
| authorships[10].institutions[0].ror | https://ror.org/02kzqn938 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I2279609970 |
| authorships[10].institutions[0].country_code | FR |
| authorships[10].institutions[0].display_name | Université de Lille |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Franck Morschhauser |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | University of Lille, Lille, France |
| authorships[11].author.id | https://openalex.org/A5107916216 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Samuel Griolet |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210107115 |
| authorships[11].affiliations[0].raw_affiliation_string | LYSARC, Statistics, Pierre-Benite, Pierre-Bénite, France |
| authorships[11].institutions[0].id | https://openalex.org/I4210107115 |
| authorships[11].institutions[0].ror | https://ror.org/0106jdf02 |
| authorships[11].institutions[0].type | other |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210107115 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | The Lymphoma Academic Research Organisation |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Samuel Griolet |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | LYSARC, Statistics, Pierre-Benite, Pierre-Bénite, France |
| authorships[12].author.id | https://openalex.org/A5110078418 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Clémentine Joubert |
| authorships[12].countries | FR |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210107115 |
| authorships[12].affiliations[0].raw_affiliation_string | Lymphoma Academic Research Organisation, Lyon, France |
| authorships[12].institutions[0].id | https://openalex.org/I4210107115 |
| authorships[12].institutions[0].ror | https://ror.org/0106jdf02 |
| authorships[12].institutions[0].type | other |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210107115 |
| authorships[12].institutions[0].country_code | FR |
| authorships[12].institutions[0].display_name | The Lymphoma Academic Research Organisation |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Clémentine Joubert |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Lymphoma Academic Research Organisation, Lyon, France |
| authorships[13].author.id | https://openalex.org/A5064941466 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Victoria Cacheux |
| authorships[13].countries | FR |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210128870 |
| authorships[13].affiliations[0].raw_affiliation_string | Clermont-Ferrand Univeristy Hospital, Clermont-Ferrand, France |
| authorships[13].institutions[0].id | https://openalex.org/I4210128870 |
| authorships[13].institutions[0].ror | https://ror.org/02tcf7a68 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210128870 |
| authorships[13].institutions[0].country_code | FR |
| authorships[13].institutions[0].display_name | Centre Hospitalier Universitaire de Clermont-Ferrand |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Victoria Cacheux |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Clermont-Ferrand Univeristy Hospital, Clermont-Ferrand, France |
| authorships[14].author.id | https://openalex.org/A5088580473 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-0680-1418 |
| authorships[14].author.display_name | Vincent Delwail |
| authorships[14].countries | FR |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I3018323443 |
| authorships[14].affiliations[0].raw_affiliation_string | chu, 86021, France |
| authorships[14].institutions[0].id | https://openalex.org/I3018323443 |
| authorships[14].institutions[0].ror | https://ror.org/01hq89f96 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I3018323443 |
| authorships[14].institutions[0].country_code | FR |
| authorships[14].institutions[0].display_name | Centre Hospitalier Universitaire de Bordeaux |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Vincent Delwail |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | chu, 86021, France |
| authorships[15].author.id | https://openalex.org/A5080009159 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | Violaine Safar |
| authorships[15].countries | FR |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210100596 |
| authorships[15].affiliations[0].raw_affiliation_string | Hospices Civils de Lyon, Pierre-Bénite, France |
| authorships[15].institutions[0].id | https://openalex.org/I4210100596 |
| authorships[15].institutions[0].ror | https://ror.org/01502ca60 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210100596 |
| authorships[15].institutions[0].country_code | FR |
| authorships[15].institutions[0].display_name | Hospices Civils de Lyon |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Violaine Safar |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Hospices Civils de Lyon, Pierre-Bénite, France |
| authorships[16].author.id | https://openalex.org/A5074402846 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-9188-3501 |
| authorships[16].author.display_name | Rémy Gressin |
| authorships[16].countries | FR |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210162920 |
| authorships[16].affiliations[0].raw_affiliation_string | chu michallon, GRENOBLE, France |
| authorships[16].institutions[0].id | https://openalex.org/I4210162920 |
| authorships[16].institutions[0].ror | https://ror.org/05kfvx519 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I2800555055, https://openalex.org/I4210162920 |
| authorships[16].institutions[0].country_code | FR |
| authorships[16].institutions[0].display_name | Hôpital Albert Michallon |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Remy Gressin |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | chu michallon, GRENOBLE, France |
| authorships[17].author.id | https://openalex.org/A5023593619 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-2070-9581 |
| authorships[17].author.display_name | Morgane Cheminant |
| authorships[17].countries | FR |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I1288880153 |
| authorships[17].affiliations[0].raw_affiliation_string | Hôpital Necker, APHP, paris, France |
| authorships[17].institutions[0].id | https://openalex.org/I1288880153 |
| authorships[17].institutions[0].ror | https://ror.org/05tr67282 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I1288880153, https://openalex.org/I4210097159, https://openalex.org/I4210120235 |
| authorships[17].institutions[0].country_code | FR |
| authorships[17].institutions[0].display_name | Hôpital Necker-Enfants Malades |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Morgane Cheminant |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Hôpital Necker, APHP, paris, France |
| authorships[18].author.id | https://openalex.org/A5072246038 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-8010-2343 |
| authorships[18].author.display_name | Marie‐Hélène Delfau‐Larue |
| authorships[18].countries | FR |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I197681013 |
| authorships[18].affiliations[0].raw_affiliation_string | APHP, GH MONDOR, UPEC university, INSERM U955, CRETEIL, France |
| authorships[18].institutions[0].id | https://openalex.org/I154526488 |
| authorships[18].institutions[0].ror | https://ror.org/02vjkv261 |
| authorships[18].institutions[0].type | government |
| authorships[18].institutions[0].lineage | https://openalex.org/I154526488 |
| authorships[18].institutions[0].country_code | FR |
| authorships[18].institutions[0].display_name | Inserm |
| authorships[18].institutions[1].id | https://openalex.org/I197681013 |
| authorships[18].institutions[1].ror | https://ror.org/05ggc9x40 |
| authorships[18].institutions[1].type | education |
| authorships[18].institutions[1].lineage | https://openalex.org/I197681013 |
| authorships[18].institutions[1].country_code | FR |
| authorships[18].institutions[1].display_name | Université Paris-Est Créteil |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Marie-Helene Delfau-Larue |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | APHP, GH MONDOR, UPEC university, INSERM U955, CRETEIL, France |
| authorships[19].author.id | https://openalex.org/A5064856085 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-2574-3874 |
| authorships[19].author.display_name | Olivier Hermine |
| authorships[19].countries | FR |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I1294671590, https://openalex.org/I154526488, https://openalex.org/I4210165077 |
| authorships[19].affiliations[0].raw_affiliation_string | INSERM U1163 CNRS ERL8254 Imagine Institute, Paris, France |
| authorships[19].institutions[0].id | https://openalex.org/I1294671590 |
| authorships[19].institutions[0].ror | https://ror.org/02feahw73 |
| authorships[19].institutions[0].type | government |
| authorships[19].institutions[0].lineage | https://openalex.org/I1294671590 |
| authorships[19].institutions[0].country_code | FR |
| authorships[19].institutions[0].display_name | Centre National de la Recherche Scientifique |
| authorships[19].institutions[1].id | https://openalex.org/I154526488 |
| authorships[19].institutions[1].ror | https://ror.org/02vjkv261 |
| authorships[19].institutions[1].type | government |
| authorships[19].institutions[1].lineage | https://openalex.org/I154526488 |
| authorships[19].institutions[1].country_code | FR |
| authorships[19].institutions[1].display_name | Inserm |
| authorships[19].institutions[2].id | https://openalex.org/I4210165077 |
| authorships[19].institutions[2].ror | https://ror.org/05rq3rb55 |
| authorships[19].institutions[2].type | facility |
| authorships[19].institutions[2].lineage | https://openalex.org/I154526488, https://openalex.org/I204730241, https://openalex.org/I4210100892, https://openalex.org/I4210165077 |
| authorships[19].institutions[2].country_code | FR |
| authorships[19].institutions[2].display_name | Institut des Maladies Génétiques Imagine |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Olivier Hermine |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | INSERM U1163 CNRS ERL8254 Imagine Institute, Paris, France |
| authorships[20].author.id | https://openalex.org/A5071962621 |
| authorships[20].author.orcid | https://orcid.org/0000-0003-0520-0493 |
| authorships[20].author.display_name | Elizabeth Macintyre |
| authorships[20].countries | FR |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I1288880153, https://openalex.org/I204730241 |
| authorships[20].affiliations[0].raw_affiliation_string | Hopital Necker, Université de Paris, Paris, France |
| authorships[20].institutions[0].id | https://openalex.org/I1288880153 |
| authorships[20].institutions[0].ror | https://ror.org/05tr67282 |
| authorships[20].institutions[0].type | healthcare |
| authorships[20].institutions[0].lineage | https://openalex.org/I1288880153, https://openalex.org/I4210097159, https://openalex.org/I4210120235 |
| authorships[20].institutions[0].country_code | FR |
| authorships[20].institutions[0].display_name | Hôpital Necker-Enfants Malades |
| authorships[20].institutions[1].id | https://openalex.org/I204730241 |
| authorships[20].institutions[1].ror | https://ror.org/05f82e368 |
| authorships[20].institutions[1].type | education |
| authorships[20].institutions[1].lineage | https://openalex.org/I204730241 |
| authorships[20].institutions[1].country_code | FR |
| authorships[20].institutions[1].display_name | Université Paris Cité |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Elizabeth A. Macintyre |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Hopital Necker, Université de Paris, Paris, France |
| authorships[21].author.id | https://openalex.org/A5016122215 |
| authorships[21].author.orcid | https://orcid.org/0000-0001-9840-2128 |
| authorships[21].author.display_name | Steven Le Gouill |
| authorships[21].countries | FR |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I80043 |
| authorships[21].affiliations[0].raw_affiliation_string | Institut Curie, Paris, France |
| authorships[21].institutions[0].id | https://openalex.org/I80043 |
| authorships[21].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[21].institutions[0].type | nonprofit |
| authorships[21].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[21].institutions[0].country_code | FR |
| authorships[21].institutions[0].display_name | Institut Curie |
| authorships[21].author_position | last |
| authorships[21].raw_author_name | Steven Le Gouill |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Institut Curie, Paris, France |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://hal.univ-lille.fr/hal-04603772/document |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10185 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Lymphoma Diagnosis and Treatment |
| related_works | https://openalex.org/W2915066039, https://openalex.org/W4385950623, https://openalex.org/W2777747661, https://openalex.org/W4386928815, https://openalex.org/W3018747034, https://openalex.org/W2902138071, https://openalex.org/W3175679928, https://openalex.org/W2988038735, https://openalex.org/W2239244313, https://openalex.org/W2970423943 |
| cited_by_count | 9 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 6 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:HAL:hal-04603772v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402512 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| best_oa_location.source.host_organization | https://openalex.org/I1294671590 |
| best_oa_location.source.host_organization_name | Centre National de la Recherche Scientifique |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1294671590 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://hal.univ-lille.fr/hal-04603772/document |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Journal articles |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Blood, 2024, Online ahead of print. ⟨10.1182/blood.2024023944⟩ |
| best_oa_location.landing_page_url | https://hal.univ-lille.fr/hal-04603772 |
| primary_location.id | doi:10.1182/blood.2024023944 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S200071133 |
| primary_location.source.issn | 0006-4971, 1528-0020 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0006-4971 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Blood |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Blood |
| primary_location.landing_page_url | https://doi.org/10.1182/blood.2024023944 |
| publication_date | 2024-04-26 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W2760635695, https://openalex.org/W2989564569, https://openalex.org/W4380083573, https://openalex.org/W4310162498, https://openalex.org/W2761878534, https://openalex.org/W3033907870, https://openalex.org/W2529212447, https://openalex.org/W3087400259, https://openalex.org/W2991957155, https://openalex.org/W2144168223, https://openalex.org/W1912693401, https://openalex.org/W3117664287, https://openalex.org/W4310780529, https://openalex.org/W2906575149, https://openalex.org/W6791525079, https://openalex.org/W3105196097, https://openalex.org/W4310106501, https://openalex.org/W3133632273 |
| referenced_works_count | 18 |
| abstract_inverted_index.2 | 7, 86, 170, 232 |
| abstract_inverted_index.= | 123, 165, 193, 210 |
| abstract_inverted_index.A | 76 |
| abstract_inverted_index.O | 47, 52, 73, 144, 184, 240 |
| abstract_inverted_index.P | 164 |
| abstract_inverted_index.R | 70, 90, 158, 223, 257 |
| abstract_inverted_index.a | 16, 187 |
| abstract_inverted_index.(O | 54, 88 |
| abstract_inverted_index.(P | 192, 209 |
| abstract_inverted_index.(R | 74 |
| abstract_inverted_index.(n | 122 |
| abstract_inverted_index.82 | 173 |
| abstract_inverted_index.At | 138 |
| abstract_inverted_index.CD | 8 |
| abstract_inverted_index.In | 112 |
| abstract_inverted_index.OS | 119, 208, 254 |
| abstract_inverted_index.We | 56 |
| abstract_inverted_index.as | 269 |
| abstract_inverted_index.at | 99, 178, 267 |
| abstract_inverted_index.by | 51 |
| abstract_inverted_index.in | 15, 35, 92, 142, 156, 169, 230, 244, 258 |
| abstract_inverted_index.of | 20, 31, 72, 94, 102, 172, 226 |
| abstract_inverted_index.to | 83 |
| abstract_inverted_index.vs | 89, 161, 196, 213 |
| abstract_inverted_index.we | 26 |
| abstract_inverted_index.(O) | 2 |
| abstract_inverted_index.(R) | 5 |
| abstract_inverted_index.85) | 124 |
| abstract_inverted_index.95% | 202, 217 |
| abstract_inverted_index.CI, | 135, 218 |
| abstract_inverted_index.HR, | 215 |
| abstract_inverted_index.MCL | 41 |
| abstract_inverted_index.MRD | 151 |
| abstract_inverted_index.PFS | 117, 191, 252 |
| abstract_inverted_index.PSM | 167 |
| abstract_inverted_index.and | 3, 108, 118, 132, 207, 243, 250, 253, 271 |
| abstract_inverted_index.are | 6 |
| abstract_inverted_index.end | 101 |
| abstract_inverted_index.had | 146, 186 |
| abstract_inverted_index.the | 28, 32, 65, 85, 100, 114, 143, 157, 183, 222, 231, 234 |
| abstract_inverted_index.was | 81 |
| abstract_inverted_index.(95% | 127, 134 |
| abstract_inverted_index.EOI, | 139 |
| abstract_inverted_index.From | 180 |
| abstract_inverted_index.MCL. | 262 |
| abstract_inverted_index.been | 13 |
| abstract_inverted_index.bone | 149 |
| abstract_inverted_index.cell | 22 |
| abstract_inverted_index.have | 11 |
| abstract_inverted_index.more | 147 |
| abstract_inverted_index.most | 235 |
| abstract_inverted_index.plus | 46 |
| abstract_inverted_index.same | 66 |
| abstract_inverted_index.sets | 171 |
| abstract_inverted_index.than | 153 |
| abstract_inverted_index.that | 10 |
| abstract_inverted_index.then | 57 |
| abstract_inverted_index.used | 82 |
| abstract_inverted_index.were | 42, 125, 228, 265 |
| abstract_inverted_index.with | 40, 44, 61, 64, 69, 175, 221, 256, 261 |
| abstract_inverted_index.χ2, | 163 |
| abstract_inverted_index.(CI), | 205 |
| abstract_inverted_index.(MRD) | 98 |
| abstract_inverted_index.(OS). | 111 |
| abstract_inverted_index.(PSM) | 80 |
| abstract_inverted_index..029; | 194 |
| abstract_inverted_index..039; | 211 |
| abstract_inverted_index.1.99; | 201 |
| abstract_inverted_index.2.08; | 216 |
| abstract_inverted_index.82.8% | 195 |
| abstract_inverted_index.83.4% | 126 |
| abstract_inverted_index.86.4% | 212 |
| abstract_inverted_index.86.9% | 133 |
| abstract_inverted_index.These | 263 |
| abstract_inverted_index.[CI], | 130 |
| abstract_inverted_index.[HR], | 200 |
| abstract_inverted_index.after | 120 |
| abstract_inverted_index.being | 238 |
| abstract_inverted_index.cause | 237 |
| abstract_inverted_index.death | 227 |
| abstract_inverted_index.group | 145, 159, 185 |
| abstract_inverted_index.never | 12 |
| abstract_inverted_index.newly | 37 |
| abstract_inverted_index.ratio | 199 |
| abstract_inverted_index.score | 78 |
| abstract_inverted_index.terms | 93 |
| abstract_inverted_index.these | 59 |
| abstract_inverted_index.those | 62, 154 |
| abstract_inverted_index.trial | 19 |
| abstract_inverted_index.which | 36 |
| abstract_inverted_index.(83.1% | 160 |
| abstract_inverted_index.(EOI), | 104 |
| abstract_inverted_index.(MCL). | 24 |
| abstract_inverted_index.(PFS), | 107 |
| abstract_inverted_index..007). | 166 |
| abstract_inverted_index.5-year | 116, 190 |
| abstract_inverted_index.63.4%; | 162 |
| abstract_inverted_index.66.6%; | 197 |
| abstract_inverted_index.71.4%; | 214 |
| abstract_inverted_index.Causes | 225 |
| abstract_inverted_index.before | 48, 241 |
| abstract_inverted_index.better | 247 |
| abstract_inverted_index.common | 236 |
| abstract_inverted_index.design | 68 |
| abstract_inverted_index.group. | 224 |
| abstract_inverted_index.hazard | 198 |
| abstract_inverted_index.longer | 188 |
| abstract_inverted_index.mantle | 21 |
| abstract_inverted_index.marrow | 150 |
| abstract_inverted_index.report | 27 |
| abstract_inverted_index.trial, | 34 |
| abstract_inverted_index.trials | 264 |
| abstract_inverted_index.Herein, | 25 |
| abstract_inverted_index.compare | 84 |
| abstract_inverted_index.control | 249 |
| abstract_inverted_index.disease | 97, 248 |
| abstract_inverted_index.group). | 55, 75 |
| abstract_inverted_index.groups) | 91 |
| abstract_inverted_index.groups, | 233 |
| abstract_inverted_index.instead | 71 |
| abstract_inverted_index.outcome | 30 |
| abstract_inverted_index.overall | 109 |
| abstract_inverted_index.treated | 43, 63, 141, 155 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.LyMa-101 | 33 |
| abstract_inverted_index.compared | 14, 58, 220, 255 |
| abstract_inverted_index.enhances | 251 |
| abstract_inverted_index.followed | 50 |
| abstract_inverted_index.frequent | 148 |
| abstract_inverted_index.interval | 129, 204 |
| abstract_inverted_index.lymphoma | 23 |
| abstract_inverted_index.matching | 79 |
| abstract_inverted_index.patients | 39, 60, 140, 174, 260 |
| abstract_inverted_index.provides | 246 |
| abstract_inverted_index.residual | 96 |
| abstract_inverted_index.resulted | 168 |
| abstract_inverted_index.survival | 106, 110 |
| abstract_inverted_index.LyMa-101, | 113 |
| abstract_inverted_index.diagnosed | 38 |
| abstract_inverted_index.estimated | 115, 189 |
| abstract_inverted_index.inclusion | 121 |
| abstract_inverted_index.induction | 103 |
| abstract_inverted_index.long-term | 29 |
| abstract_inverted_index.lymphoma. | 239 |
| abstract_inverted_index.rituximab | 4 |
| abstract_inverted_index.treatment | 67, 181 |
| abstract_inverted_index.1.01-4.16) | 219 |
| abstract_inverted_index.1.05-3.76) | 206 |
| abstract_inverted_index.73.5-89.8) | 131 |
| abstract_inverted_index.antibodies | 9 |
| abstract_inverted_index.comparable | 176, 229 |
| abstract_inverted_index.confidence | 128, 203 |
| abstract_inverted_index.inclusion. | 179 |
| abstract_inverted_index.measurable | 95 |
| abstract_inverted_index.negativity | 152 |
| abstract_inverted_index.propensity | 77 |
| abstract_inverted_index.randomized | 18 |
| abstract_inverted_index.registered | 266 |
| abstract_inverted_index.77.6-92.5), | 136 |
| abstract_inverted_index.initiation, | 182 |
| abstract_inverted_index.maintenance | 53, 245 |
| abstract_inverted_index.populations | 87 |
| abstract_inverted_index.prospective | 17 |
| abstract_inverted_index.#NCT00921414 | 270 |
| abstract_inverted_index.NCT02896582. | 272 |
| abstract_inverted_index.Obinutuzumab | 1 |
| abstract_inverted_index.chemotherapy | 45 |
| abstract_inverted_index.respectively. | 137 |
| abstract_inverted_index.characteristics | 177 |
| abstract_inverted_index.transplantation | 242 |
| abstract_inverted_index.progression-free | 105 |
| abstract_inverted_index.transplantation, | 49 |
| abstract_inverted_index.transplant-eligible | 259 |
| abstract_inverted_index.www.clinicaltrials.gov | 268 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 96 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 22 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6899999976158142 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.95866114 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |